欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号DE/H/0299/003
药品名称Levocetirizin Saft
活性成分
    • Levocetirizine dihydrochloride 0.5 mg/ml
剂型Oral solution
上市许可持有人UCB Pharma GmbH Alfred-Nobel-Str. 10 40789 Monheim Germany
参考成员国 - 产品名称Germany (DE)
互认成员国 - 产品名称
    • Denmark (DK)
    • Belgium (BE)
    • Netherlands (NL)
      Xyzal 0.5 mg/ml drank
    • Luxembourg (LU)
    • United Kingdom (Northern Ireland) (XI)
    • Ireland (IE)
    • France (FR)
    • Spain (ES)
    • Portugal (PT)
      Xyzal
    • Italy (IT)
    • Greece (GR)
    • Norway (NO)
    • Finland (FI)
    • Poland (PL)
      Xyzal
    • Latvia (LV)
      Xyzal 0,5 mg/ml šķīdums iekšķīgai lietošanai
    • Lithuania (LT)
      Xyzal 0,5 mg/ml geriamasis tirpalas
    • Estonia (EE)
      Xyzal
    • Hungary (HU)
      XYZAL 0,5 mg/ml belsőleges oldat
    • Cyprus (CY)
      XYZAL ORAL SOLUTION 0.5MG/ML
    • Czechia (CZ)
    • Slovakia (SK)
      Xyzal 5 mg/10 ml perorálny roztok
    • Slovenia (SI)
    • Malta (MT)
      XYZAL
许可日期2006/05/09
最近更新日期2025/01/27
药物ATC编码
    • R06AE09 levocetirizine
申请类型
  • TypeLevel1:Known Active Substance
  • TypeLevel2:Initial Application
  • TypeLevel3:Full Dossier Art 8.3(i) Dir 2001/83/EC
  • TypeLevel4:Chemical Substance
  • TypeLevel5:Prescription Only
附件文件下载
市场状态Positive
©2006-2025 Drugfuture->European Union HMA Authorisation of Medicines DataBase